Myomo (NYSEAMERICAN:MYO) Price Target Raised to $11.00

Myomo (NYSEAMERICAN:MYO) had its price target upped by Craig Hallum from $9.00 to $11.00 in a research report report published on Tuesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on MYO. Ascendiant Capital Markets lifted their target price on Myomo from $8.50 to $9.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $7.50 price objective on shares of Myomo in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Myomo presently has an average rating of “Buy” and a consensus price target of $9.25.

Myomo Trading Down 6.6 %

NYSEAMERICAN MYO opened at $5.07 on Tuesday. The firm has a market cap of $153.37 million, a PE ratio of -22.04 and a beta of 1.68. Myomo has a one year low of $2.51 and a one year high of $7.17.

Insider Buying and Selling

In other Myomo news, insider Harry Kovelman sold 30,000 shares of Myomo stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares of the company’s stock, valued at $538,851.50. The trade was a 23.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC purchased a new position in shares of Myomo during the third quarter worth about $36,000. Jane Street Group LLC purchased a new position in shares of Myomo during the third quarter worth about $65,000. GSA Capital Partners LLP grew its holdings in shares of Myomo by 60.8% during the third quarter. GSA Capital Partners LLP now owns 103,342 shares of the company’s stock worth $414,000 after purchasing an additional 39,085 shares in the last quarter. Calamos Advisors LLC purchased a new position in shares of Myomo during the fourth quarter worth about $189,000. Finally, Stonepine Capital Management LLC bought a new stake in Myomo in the 3rd quarter worth approximately $401,000. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.